Today s news on AEZS 140 strengthens my case that AEZS is getting out of R&D
Probably confirms that AEZS 108 Phase 3 trial has failed.......or that they think it will fail
I have no inside knowledge but I have a feeling that the licensing of AEZS120 is a step towards a new business model
1-I think they know that aezs108 willl fail or has failed because it is an open label trial
2-they still believe in a successful trial and eventual market success for Aezs-130
3-they will refrain from any pre clinical or clinical development expenses and will conduct no more R&D
Excrpt for Aezs 130
3-they will try to license other compounds
4-they will reduce the burn rate to less than a million a month which they may cover with cash flow from estrogel and saizen???
5-they will fund aezs 130 trial with cash on hand which should be enough to carry them till the positive expected results
So number if employess goes down to 10 or so
No bankruptcy but no big returns either
Really I dont see any other way out
Unless I am wrong about phase 3 trial on endometrial with aezs 108
But the odds of successful aezs trial are very remote IMO otherwise it would have been partnered
Just a very wild guess!!!
Dodd must be very surprised at the negative effect of the cashless warrants!!
He had no clue that this was going to happen
I am expecting Dodd to bite the bullet and fire the CFO
Please explain money -is raining what will be the trigger for declaring the end of the warrant conversions...You seem to be vey knowledgeable and I trust that your reply will be detailed and would also like to know how you think the PR will be worded but just briefly
In a previous post I mentioned that maybe the company is expecting the SP to rise within the extension period thus delaying the RS to get a lower reverse rate.
What if the real reason for delaying the RS is that they expect the SP trend even lower than today's due to the cashless exercise of warrants and other events......
I know about the pipeline...they still own a Right and quasi ownership on discoveries in the area of oncology ,neurology endocrinology and women s health.You may argue that the commercial value today is ZERO and you are probably right.
The odds of negative clinical results are certainly greater than positive results and this is probably why Turpin went for the last toxic dilution....I dont think he has ever believed in the chance of success of any of the company s compounds but still the lure created by oncoming clinical trial results has allowed him over 20 years not only to keep getting his paycheck but also becoming wealthy......EURK !!!!
The PR does not state when the extension was granted.....it just says ...announced today that an.....
It seems very likely that the extension was received prior to the 9 million trading day at the beginning of the week,,,and the news fot out before being released to the retail shareholders .....Governance sucks at AEZS
I have a feeling that they expect the the SP will appreciate somehow.....Maybe they are negotiating to partner AEZS 108..or trying to sell part of the pipeline.....As you rightly point out no clinical trial results are expected within the extension period UNLESS the endo trial is suddenly producing fantastic results and is stopped for efficacy
The most probable reason from my years of following AEZS is simply a smokescreen to try to increase the SP prior to some more dilutive action,
yes I know.....I was just trying to show the discrepancy between the two sites,,,,Recall that Cetrorelix was a complete disaster .....will Ozarelix be any different?
Still shows up on Spectrum s website as a promising drug
All it says about STATUS is PHase 2
Does not mention completed
I really think that goma speaks the truth....he was told that they were filing an extension......which means that they will do the opposite.....That is how they operate
Your post fails to mention the members of the Board of Directors who in my opinion have relinquished their fiduciary responsibilities since a long long time ago...They have relied over the years on misinformation from management and since most of the Directors have no prior experience in biotechs they were not able to challenge management opinions .Most of them should have recognized their failure but instead they all allowed their names to be part of the slate being too happy to collect fees and perks......Turpin and Dodd love them ....they are their puppets .....